Copeptin constitutes a novel biomarker of degenerative aortic stenosis

Heart and Vessels

Volumn 28, Issue 5, 2013, Pages 613-619

  Mizia Stec, Katarzyna ^a   Lasota, Bartosz ^a   Mizia, Magdalena ^a   Chmiel, Artur ^a   Adamczyk, Tomasz ^a   Chudek, Jerzy ^a   Gasior, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Aortic stenosis; Copeptin; N terminal proBNP; Natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; COPEPTIN;

ADULT; AORTA STENOSIS; AORTA VALVE STENOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SYSTOLE; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84884673694     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-012-0293-y     Document Type: Article

References (24)

1. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD, Miyake-Hull CY, Schwaegler RG (1997) Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95:2262-2270
2. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H (2000) Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343:611-617
3. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, Barnes ME, Tajik AJ (2005) Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111:3290-3295
4. Maekawa Y, Kawamura A, Furuta A, Yuasa S, Fukuda K (2011) A case of severe aortic stenosis with severe coronary artery disease that was successfully treated by balloon aortic valvuloplasty and percutaneous coronary intervention. Heart Vessels. doi: 10.1007/s00380-011-0208-3
5. Furuta A, Shimizu H, Hachiya T, Ohno Y, Kawajiri H, Kawamura A, Kokaji K, Yozu R, Fukuda K (2012) Time to revisit role of transcatheter balloon aortic valvuloplasty: a bridge-therapy to subsequent treatment case report. Heart Vessels. doi: 10.1007/s00380-012-0268-z
6. Cemri M, Arslan U, Kocaman SA, Cengel A (2008) Relationship between N-terminal pro-B type natriuretic peptide and extensive echocardiographic parameters in mild to moderate aortic stenosis. J Postgrad Med 54(1):12-16
7. Gerber IL, Legget ME, West TM, Richards AM, Stewart RA (2005) Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 95(7):898-901
8. Weber M, Arnold R, Rau M, Brandt R, Berkovitsch A, Mitrovic V, Hamm C (2004) Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 94(6):740-745
9. Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R (2006) Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 36:771-778
10. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Begmann A, Haltmayer M, Mueller T (2007) Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13:42-49
11. Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgethaler NG, Davies JE, Ng LL (2008) C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 14(9):739-745
12. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ (2008) Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 12:R11
13. Luyt CE, Guerin V, Combes A, Trouillet JL, Ayed SB, Bernard M, Gibert C, Chastre J (2005) Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 171:48-53
14. Katan M, Morgenthaler N, Dixit K, Rutishauser J, Brabant G, Muller B, Christ-Crain M (2007) Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 92:2640-2643
15. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112-119
16. Evangelista A, Flachskampf FA, Erbel R, Antonini-Canterin F, Vlachopoulos C, Rocchi G, Sicari R, Nihoyannopoulos P, Zamorano J (2010) Echocardiography in aortic diseases: EAE recommendations for clinical practice on behalf of the European Association of Echocardiography. Eur J Echocardiogr 11:645-658
17. Goldsmith SR (2002) Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail 8:251-256
18. Fukuzawa J, Haneda T, Kikuchi K (1999) Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat hear via the V1 receptor. Mol Cell Biochem 195:93-98
19. Goldsmith SR (1987) Vasopressin as vasopressor. Am J Med 82:1213-1219
20. Fan YH, Zhao LY, Zheng QS, Dong H, Wang HC, Yang XD (2007) Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. Life Sci 81:327-335
21. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL (2007) C terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115:2103-2110
22. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R (2008) Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 52:266-272
23. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K (2009) C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 30:1187-1194
24. Alehagen U, Dahlström U, Rehfeld JF, Goetze J (2011) Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 305(20):2088-2095